Press Release

Microfluidics Market to Grow with a CAGR of 22.70% through 2029

Rising demand for point-of-care testing and increasing number of the elderly population & the spread of chronic diseases worldwide is expected to drive the Global Microfluidics Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Microfluidics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Microfluidics Market stood at USD 24.48 Billion in 2023 and is anticipated to grow with a CAGR of 22.70% in the forecast period, 2025-2029. The anticipated increase in demand for point-of-care (POC) devices is expected to significantly boost the market size in the coming years. There is a notable demand for low-volume sample analysis, In Vitro Diagnostics (IVD), high-throughput screening methodologies, and the development of advanced lab-on-a-chip technologies, which further contribute to the market growth of microfluidics over the analysis timeframe. Microfluidics offers a high return on investment and helps control costs by minimizing errors. Other key factors driving the market growth for microfluidics include the increasing adoption of microfluidics technology and devices in point-of-care diagnostics, advancements in diagnostic devices, and the rising incidence of chronic diseases worldwide. These factors collectively contribute to the growing demand for molecular diagnosis and positively impact the market growth of microfluidics.                                                                                        

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Microfluidics Market

Microfluidic devices offer a significant advantage in the analysis of small sample volumes, reducing reagent waste and preserving hard-to-produce samples. The demand for low-volume sample devices has been driven by the introduction of microfluidics devices and the increased research activities of analytical and clinical researchers. Compared to the conventional method of genome analysis, which requires decoding the entire DNA, microfluidics devices require only a small volume of samples for data interpretation, thereby reducing analysis costs and time. The adoption of microfluidics has enabled the miniaturization of conventional laboratory procedures onto a lab-on-a-chip platform.

The introduction of point-of-care diagnostics by multiple market players has facilitated early disease diagnosis and reduced hospital visits. With advancements in technology, market players now differentiate their products by incorporating minimally invasive features, accuracy, and speed. Microfluidics has thus made significant contributions to the in-vitro diagnostics (IVD) market. Leading market players such as Abbott, Roche, and Danaher have already integrated microfluidics technology into their existing diagnostic devices.

Furthermore, key players are exploring digital microfluidics, with HORIBA collaborating with SigTuple to expedite the deployment of its AI100, an AI-assisted digital pathology solution, in the Indian subcontinent. SigTuple's smart diagnostic solutions, combining AI, robotics, microfluidics, and cloud computing, aim to provide accessible and affordable quality healthcare. The increasing adoption of microfluidics devices in various research and diagnostic fields has prompted industry players to introduce advanced technologies to capture potential market share. Many companies are currently trialing their devices and anticipate commercialization. For example, BIOLASE, Inc. and EdgeEndo received FDA 510(k) clearance for the EdgePRO system in January 2023. This system offers an enhanced disinfection and cleaning alternative for root canal procedures, utilizing laser-aided microfluidic irrigation without disrupting workflow or significantly increasing costs per procedure. In addition, the Loschmidt laboratories team and partners from ETH Zurich developed a microfluidic platform in March 2021 for rapid investigation of enzymes and their properties.

The Global Microfluidics Market is segmented into technology, material, application, regional distribution, and company

Based on the Material, the market is divided into several categories: Silicon, Glass, Polymer, PDMS, and others. The market for microfluidics was predominantly influenced by the Polydimethylsiloxane (PDMS) segment. Among various polymers, PDMS has gained significant popularity, especially in microfluidic devices for rapid prototyping. This can be attributed to the wide acceptance of PDMS among academic professionals, primarily due to its ease of manufacturing and cost-effectiveness. Notable characteristics of PDMS include flexibility, transparency, biocompatibility, and gas permeability. However, it is important to note that PDMS has some limitations, such as weak IR transmission behavior and a longer curing time, which make it comparatively more challenging to work with.

Based on region, North America segment is expected to grow during the forecast period. North America dominates the microfluidics market and is expected to hold a significant share over the forecast period. This can be attributed to factors such as the well-established healthcare system and the higher adoption of novel therapeutics among the general population. Additionally, the region has witnessed an increasing prevalence of infectious and chronic diseases, further driving the demand for microfluidic technologies. The field of microfluidics in North America is experiencing substantial growth, with considerable investments in research and development.

For instance, data updates from September 2021 indicate that PhRMA member companies have invested over USD 1.1 trillion in the search for new treatments and cures, including USD 102.3 billion in 2021 alone. These investments are expected to contribute to the growth of the microfluidics segment during the forecast period. Point-of-care diagnostics, utilizing microfluidic technology, play a crucial role in various applications such as molecular diagnostics, infectious diseases, and chronic diseases. The aim is to develop integrated microfluidic devices that are user-friendly and provide rapid results. In August 2020, researchers from the University of Illinois at Urbana-Champaign showcased a prototype of a rapid COVID-19 molecular test and a portable instrument for result interpretation using a smartphone, eliminating the need for laboratory testing.

Furthermore, the market in the North American region is boosted by the continuous product launches by key market players. For example, LexaGene launched the MiQLab system for the detection of the SARS-CoV-2 virus, expanding its use from research-only to point-of-care applications, after receiving emergency use authorization (EUA) in the United States in January 2021. Similarly, LumiraDx submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) in October 2021. This microfluidic immunofluorescence assay enables quick verification of infection for patients suspected of flu and COVID-19, aiding in diagnosis and clinical decision-making.  

Major companies operating in Global Microfluidics Market are:

  • UFluidix
  • Bio-Rad Laboratories Inc.
  • Emulate Inc.
  • Dolomite Microfluidics (Blacktrace Holdings Ltd)
  • Sphere Fluidics Limited
  • FluIdigm Corporation
  • Illumina Inc.
  • Micronit Microfluidics
  • PerkinElmer Inc.
  • Hesperos Inc. 

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The increasing demand for microfluidics technology, advancements in diagnostic equipment, and the rising prevalence of chronic diseases are significant drivers for market expansion. However, the utilization of microfluidics in healthcare is accompanied by the development of regulatory criteria, leading to delays in the approval of microfluidic devices and hindering market growth. Additionally, the incorporation of emerging microfluidics technology in existing applications poses an additional barrier to market expansion. Consequently, businesses are allocating resources to address these challenges. Rapid technological advancements in the healthcare and pharmaceutical sectors are expected to drive the demand for microfluidics-based products in the coming years. Currently, microfluidics is extensively utilized in drug discovery and development, clinical diagnostics, genomics, and proteomics. Furthermore, the increasing popularity of portable diagnostic devices is anticipated to contribute to the growth of the microfluidics market in the near future.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Microfluidics Market Segmented By Technology (Medical/Healthcare, Non-medical), By Material (Silicon, Glass, Polymer, PDMS, Others), By Application (Lab-on-a-chip, Organs-on-chips, Continuous flow microfluidics, Optofluidics and microfluidics, Acoustofluidics and microfluidics, Electrophoresis and microfluidics), By Region and Competition”, has evaluated the future growth potential of Global Microfluidics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Microfluidics Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News